Biovivium Strategies’ Post

🌟 Excited to share a thought-provoking publication titled "Evolution of Mesenchymal Stem Cell Therapy as an Advanced Therapeutic Medicinal Product (ATMP)".📚 In this intriguing review, the authors delve into the rapidly developing field of stem cell therapy and its potential for regenerative medicine. Stem cells, with their ability to self-renew and differentiate into different cell types, hold immense promise for individuals with severe diseases that are resistant to conventional treatments. 🧬 Specifically, the review focuses on the evolution of mesenchymal stem cell-based therapy as an ATMP in both the global and Indian contexts. Guidelines governing their usage and the clinical application of these innovative therapeutics are also discussed.🌍 If you're curious about the latest advancements in stem cell research and the potential impact on healthcare, I highly recommend giving this publication a read! 📖 Feel free to share your thoughts and insights. Let's foster a discussion on the future of medical advancements! 👉 https://lnkd.in/g9hQvWym. #StemCellResearch #RegenerativeMedicine #ATMP #Healthcare

Compelling case report on the application of Adipose Derived Stem Cells treating Chronic Ulcer's ✅ - The document discusses the potential of adipose-derived stem cells (ADSC) as a novel treatment for chronic ulcers, emphasizing their safety, efficacy, and ease of harvest compared to bone marrow-derived stem cells. - It reviews nine clinical trials and fourteen registered trials, identifying a significant disparity in study design and patient population. - The document highlights the challenges posed by chronic leg ulcers, their impact on patients and healthcare systems, and the potential of stem cell therapy as a new treatment option. - It delves into the properties of ADSC, emphasizing their abundance, ease of harvest, and superior yield compared to bone marrow-derived stem cells. - The review provides valuable insights into the current status of treating chronic ulcers with stem cells What are your thoughts? #regenerativemedicine #stemcells #medicalinnovation #allmedica #chroniculcers

🔬 Exciting News in Organoid Research for COVID-19! 🦠 Thrilled to unveil our cool findings in leveraging iPSC-based vascular organoid technology to illuminate a potential therapeutic pathway for COVID-19 at Cell Stem Cell. Key Insight: Endotheliopathy is a known hallmark of severe COVID-19. Our research began establishing a human vascular organoid model via the venous progenitor route from induced pluripotent stem cells, mirroring the damage induced by SARS-CoV-2 infection in a dish. By intertwining patient serum proteome, organoid transcriptome, engineered human blood vessel analysis, and non-human primate study, we discovered that the severe vascular damage and thrombosis linked with COVID-19 could be alleviated by a long-acting monoclonal antibody targeting the complement amplification cycle regulated by factor D (CFD). This will pave the way for a deeper understanding of the virus's impact on the human vascular system and, more importantly, a novel approach to treating endotheliopathy in COVID-19. 🌐 Full article: https://lnkd.in/gu-rdnWs 🌐 Featured article: https://lnkd.in/gsKdUfyw 🌐 Blog post: https://lnkd.in/ge6AgD5w This work has been carried out in collaboration with #Takeda, #TokyoMedicalAndDentalUniversity, #CincinnatiChildrens, #OsakaUniversity, #NagoyaUniversity, #KyotoUniversity, and #ShigaUniversityOfMedicalScience during the middle of pandemic, and our study on human vascular organoids has some promising insights. I'm incredibly proud of the dedication and hard work of our multi-disciplinary team spearheaded by Eri Kawakami, Yasunori Nio (Takeda) and Norikazu Saiki(Tokyo Medical and Dental University). Congrats to the team! #COVID19 #Organoid #Research #HealthcareInnovation #Science #iPSC #CollaborativeResearch #PandemicResponse

We're thrilled to share our latest research on human placental mesenchymal stem cells (hPMSCs) and their derived extracellular vesicles (EVs) as a potential therapy for acute respiratory distress syndrome (ARDS)! This important work highlights the promising role of placental MSCs and their EVs in ameliorating lung injury and improving outcomes in ARDS. Our study, published in the journal MDPI Cells, demonstrates that hPMSCs and EVs effectively reduce inflammation and tissue damage in a murine model of ARDS. These findings pave the way for further investigation into the potential of hPMSCs and EVs as a novel therapeutic approach for ARDS patients. ARDS is a devastating respiratory condition with limited treatment options. The development of effective therapies is crucial for improving patient survival and quality of life. We are excited about the potential of hPMSCs and EVs to revolutionize ARDS treatment. Our research is a significant step towards this goal, and we are committed to continuing our efforts to bring this promising therapy to patients. Read our full article here: https://lnkd.in/d6RWEjA5 #ards #stemcells #inflammation #exosomes #covid19 #advancedtherapies Cells MDPI; KELI Therapeutics; Lietuvos sveikatos mokslų universitetas (LSMU)

📣 New star paper sharing 📣 📃 Title: Immune response: the Achilles’ heel of the stem cell-based regenerative therapies ✒ Authors: Cláudia S Oliveira and Freni K. Tavaria 🎯 In the next future, the conjunction of multiple parameters may facilitate the development of new therapeutic tools based on the use of mesenchymal and hematopoietic-derived cells and products that clearly influence the immune response and improve tissue regeneration in a more personalized way for clinical applications. #Mesenchymalstemcells #hematopoieticstemcells #tissueregeneration #immuneresponse #immunomodulation 🔎 Read the full article at https://lnkd.in/gduKgj8h

Answering your questions about the legality of live stem cell treatments in the United States. 🧬 🇺🇸 In this video Dr. Travis Whitney discusses the legality of live umbilical cord-derived stem cells. These particular stem cell treatments are legal in the United States due to several factors, primarily centered around regulatory approvals and clinical applications. These stem cells are obtained from donated umbilical cord blood or tissue, which is typically considered to be minimally manipulated and poses lower risks. In the United States, the Food and Drug Administration (FDA) regulates stem cell therapies. Umbilical cord-derived stem cells fall under the category of minimally manipulated autologous stem cells, as they are often derived from a person's own umbilical cord or donated cord blood. This categorization means that these stem cells are generally considered safe and not subject to the same rigorous regulations as more complex, drug-like therapies. While live umbilical cord-derived stem cells are legal in the United States, the perception that overseas clinics offer unique or superior treatment options may persist due to a combination of misinformation, expanded treatment options, and cost considerations. It's crucial for individuals considering stem cell therapy to thoroughly research the available treatments, and consult with reputable medical professionals. If you have any questions about stem cell treatment or the amazing results from regenerative medicine, call us at 602.603.3118 or check out https://lnkd.in/ekqcpBdD #regenerativemedicine #stemcelltherapy #legalityofstemcells #innatehealthcare #cuttingedgemedtech

📣 New star paper sharing 📣 📃 Title: Immune response: the Achilles’ heel of the stem cell-based regenerative therapies ✒ Authors: Cláudia S Oliveira and Freni K. Tavaria 🎯 In the next future, the conjunction of multiple parameters may facilitate the development of new therapeutic tools based on the use of mesenchymal and hematopoietic-derived cells and products that clearly influence the immune response and improve tissue regeneration in a more personalized way for clinical applications. #Mesenchymalstemcells #hematopoieticstemcells #tissueregeneration #immuneresponse #immunomodulation 🔎 Read the full article at https://lnkd.in/g4p-tv48

Mesenchymal stem cells (MSCs) are not just cells but potential game-changers as disease modifiers. Gallant works to set a new standard in #animalhealth. MSCs have shown promise in #regenerativemedicine, tissue engineering, and treating various diseases. Explore our scientific approach and how we're blazing a path to bring off-the-shelf stem cell therapies to pets suffering from debilitating diseases. https://bit.ly/3RjB71X #biotechnology #innovation #stemcells

Researchers from the Second Xiangya Hospital, Central South University, and the People's Hospital of Jianyang City have published a groundbreaking review in Frontiers in Bioengineering and Biotechnology. Their work sheds light on the potential of induced pluripotent stem cell-derived mesenchymal stem cells (iMSCs) and their extracellular vesicles (iMSC-EVs) in immunotherapy. Key highlights: --iMSCs offer a promising alternative to traditional MSCs for immune-related diseases --iMSC-EVs show potential for "cell-free therapy" applications --Comprehensive analysis of iMSCs' impact on immune cells and disease applications #StemCellResearch #Immunotherapy #ChineseBiotech #RegenerativeMedicine #PersonalizedMedicine